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ABSTRACT 
Development of nanoparticle (NP) based therapies to promote regeneration in sites of central nervous 
system (CNS; i.e. brain and spinal cord) pathology relies critically on the availability of experimental models 
that offer biologically valid predictions of NP fate in vivo. However, there is a major lack of biological models 
that mimic the pathological complexity of target neural sites in vivo, particularly the responses of resident 
neural immune cells to NPs. Here, we have utilised a previously developed in vitro model of traumatic spinal 
cord injury (based on 3-D organotypic slice arrays) with dynamic time lapse imaging to reveal in real-time the 
acute cellular fate of NPs within injury foci. We demonstrate the utility of our model in revealing the well 
documented phenomenon of avid NP sequestration by the intrinsic immune cells of the CNS (the 
microglia). Such immune sequestration is a known translational barrier to the use of NP-based therapeutics 
for neurological injury. Accordingly, we suggest that the utility of our model in mimicking microglial 
sequestration behaviours offers a valuable investigative tool to evaluate strategies to overcome this cellular 
response within a simple and biologically relevant experimental system, whilst reducing the use of live 
animal neurological injury models for such studies. 
 
 
 
 
1   Introduction 
 
Nanotherapeutic strategies for neurological injury 
and disease (in areas such as  neuroimaging,  drug 
and gene delivery) are gaining increasing popularity 
in the burgeoning field of nanomedicine, particularly 
applications  involving  nanoparticles  (NPs)  [1–4]. 
Extensive efforts have been focused on developing 
strategies to deliver NP-based therapeutic agents into 
sites of neurological pathology. Most studies focusing 
on development of nanoparticle based therapeutics for 
neurological injury/disease usually address delivery 
of such agents across the protective blood brain barrier 
surrounding neural tissue. However the majority of 
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such studies have neglected to consider the role 
of the immune component of the nervous system 
itself. From research in recent years it has become 
apparent that such delivery strategies will need to 
take account of a major barrier to therapeutic NP 
delivery imposed by these resident immune cells of 
the brain and spinal cord—namely the “microglia” 
[5–7]. Microglia are highly phagocytic and motile 
immune cells present throughout the central 
nervous system (CNS), and are involved in 
constant surveillance of their local 
microenvironment for identification and removal of 
“foreign” material [7, 8]. Microglia have been shown 
to dominate uptake versus other neural cell types due 
to their comparatively rapid and extensive particle 
uptake profiles [9]. This has been demonstrated for 
different NP types, using defined glial co-cultures [9], 
undefined co-cultures of primary neurons and glial 
cells, and more complex transverse organotypic spinal 
cord slices (intact tissue) co-cultured with peripheral 
nerve grafts [10]. Together, it is estimated that the 
glial cells account for up to 99.5% of cellular uptake of 
NPs, with microglia shown to be responsible for the 
majority of this uptake in vivo [11]. The high clinical 
relevance of this phenomenon is reflected in in vivo 
studies that replicate these observations of microglial 
dominance of uptake following direct delivery of NPs 
to the CNS [11–13]. Injection of aminosilane-
coated superparamagnetic iron oxide NPs (core 
diameter 15 nm) into glioblastoma tumours for 
thermotherapy reveals that the NPs are 
overwhelmingly localised in microglia/macrophage-
like cells [13]. In striking con- trast, other cell types 
in the brains of these patients, such as the target 
glioblastoma cells and reactive astro- cytes rarely 
displayed intracellular NPs. This result is not due to 
tumour cells lacking the capacity for NP uptake, as 
experiments using isolated gliosarcoma and glioma 
cells in vitro (i.e. in the absence of microglial cells) 
demonstrate that tumour cells can take up NPs—
observations which would have erroneously 
predicted efficient tumour cell uptake in the intact CNS 
[12]. Similarly, when injected into sites of transecting 
spinal cord injury (SCI) in rodents, Spherofluor NPs 
(approx. 360 nm diameter) showed localisation exclu- 
sively to immune cells (our unpublished data). We have 
also shown that in line with their phagocytic roles, 
microglia  inactivate  particles  by  sequestration  into 
vesicles and extensive lysosomal degradation [14]. 
Such observations highlight an important clinical 
challenge confronting NP delivery into the CNS par- 
ticularly for sites of neurological injury and disease 
where large numbers of activated microglia exist. They 
additionally highlight the need for the development 
of multicellular experimental model systems, wherein 
post-injury pathological processes and the microglial 
barrier can be effectively replicated, for the develop- 
mental testing of therapeutic approaches to overcome 
the barrier imposed by microglial clearance. Live 
animal neurological injury models represent the most 
biologically relevant experimental systems in this 
context, but the relative inaccessibility of the brain and 
spinal cord for experimental manipulation necessitate 
highly invasive procedures with several attendant 
ethical and practical drawbacks [11, 15–17]. There 
is therefore a major need for alternative, biomimetic 
models to Reduce, Refine and Replace live 
animal use in neuro-nanotechnology studies [18]. 
Despite this need, studies demonstrating 
competitive microglial clearance and the related 
barrier to uptake in other neural cell types have 
generally used simple, undefined co-culture systems 
[10] which overall fail to replicate the complex cyto-
architecture of neural tissue [19]. It should also be 
noted that all of these previous studies did not 
incorporate a neurological injury component and are 
therefore limited in their ability to mimic the 
intricate environment of neurological injury sites, 
wherein multiple cell types with specialised functions 
co-exist. 
In this context, a novel in vitro model of SCI 
described by ourselves recently could provide a 
technically facile but valuable experimental tool for 
studying microglial particle uptake dynamics within 
an injury-simulated environment [20]. This  model 
is based on the use of 3-D spinal cord tissue 
arrays within which a focal, traumatic injury can be 
induced severing the nerve fibres, mimicking for 
example injuries due to knife/gunshot wounds. We 
previously demonstrated that major pathological 
features of neurological injury in vivo, such as the 
formation of a glial cell scar and an age related 
decline in nerve fibre regeneration were all 
mimicked in the injury foci— highlighting the 
model’s  relevance  to  CNS  injury in vivo [20]. 
Importantly, injury foci were found to 
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be progressively infiltrated by microglial cells which 
showed highly activated phenotypes characteristic of 
pathological sites. Despite the neuro-mimicry offered 
by the model, it is not known whether  it  can  be 
used to replicate competitive sequestration of NPs 
by microglia in neural pathology sites, or to mimic 
intercellular differences in NP uptake profiles as seen 
in vivo. If such a demonstration can be shown to 
be successful, then our model could provide a 
powerful tool to study the microglial barrier and 
investigate pharmaceutical approaches to overcome 
it. Here, we have delivered a well-characterised NP 
into spinal cord slice injury sites; using a combination 
of dynamic live-cell and confocal imaging, we 
document cellular particle uptake and sequestration 
profiles by the microglia versus other major neural 
cell populations in the simulated injury foci. 
 
2 Materials and methods 
The care and use of animals was in accordance 
with the Animals (Scientific Procedures) Act of 1986 
(UK) with local ethics committee approval. 
 
2.1 Reagents and equipment 
 
Tissue culture plastics, media and supplements were 
from Fisher Scientific (Loughborough, UK) and 
Sigma Aldrich (Poole, UK). Millicell culture inserts 
(PICM0RG50) and Omnipore membranes 
(JHWP04700) were from Millipore (Watford, UK). 
Spherofluor (SpheroTM) magnetic NPs (comprising a 
polystyrene core stained with the fluorescent dye 
Nile red, within a composite layer of polystyrene and 
iron oxide, coated with carboxylic acid groups) 
were obtained from Spherotech Inc. (Lake Forest, 
Illinois, USA). The NP used in this study has been 
shown to accumulate in areas of transecting SCI 
(the in vivo counterpart to the injury model used in 
the current study and which is associated with 
breakdown of the blood-spinal cord barrier) after 
intravenous delivery in rodents [21], and has been 
well-characterised by electron microscopy, zeta-
sizer analysis, powder X-ray diffraction and Fourier 
transform infrared spectroscopy (200–390 nm 
diameter, mean 360 nm; –14 mV zeta-potential; iron 
content 15%–20% w/v) [14]. The live/dead cell viability 
 
kit was from Invitrogen (Paisley, UK). Vectashield 
mounting medium containing 4’,6-diamidino-2- 
phenylindole (DAPI) was from Vector Laboratories 
(Peterborough, UK). Primary antibodies were: rat 
anti-CD11b (clone 5C6, MCA711GT; Bio-Rad, UK), 
rabbit anti-Cx3cr1 (TP501; amsbio, UK), rabbit anti-glial 
fibrillary acidic protein (GFAP) from DakoCytomation 
(Ely, UK), rat anti-myelin basic protein (MBP) from 
Serotech (Kidlington, UK) and rabbit anti-neuronal 
class III β-tubulin (clone TUJ-1) from Covance 
(Princeton, NJ). Fluorescein isothiocyanate (FITC)- 
conjugated secondary antibodies were from 
Jackson ImmunoResearch Laboratories Inc. (West 
Grove, PA, USA), except FITC-conjugated anti-
biotin secondary antibody, which along with biotin-
conjugated lectin (from Lycopersicon esculentum) 
and dexamethasone (DEX) 21-phosphate disodium 
(D4902; ≥97% pure) was from Sigma Aldrich (Poole, 
UK). 
 
2.2 Preparation and lesioning of organotypic 
spinal cord slice cultures 
 
Spinal cord slice cultures were generated and lesioned 
as described previously [20, 22, 23]. Briefly, 
mouse pups aged 1–3 postnatal days (P1–3) were 
terminally anaesthetised, decapitated and a midline 
incision was made along the length of each spine. 
The spinal cords (approximately 10 mm in length) 
were rapidly dissected out from the thoracolumbar 
region and placed in ice-cold slicing medium 
(Earle’s balanced salt solution, EBSS, buffered with 
25 mM HEPES). The cords were transferred onto 
the chopping plate of a McIlwain tissue chopper and 
sliced  lengthways  in the parasagittal plane (350 μm 
thickness) to produce five to seven usable slices per 
cord. Intact slices were transferred to Omnipore 
membranes, resting on the Millicell culture insert 
membrane within 35 mm Petri dishes (Fig. 1(a)(1)). 
Slices were cultured at the air- medium interface 
with an 80% medium change every two days (50% 
modified Eagles’ medium (MEM), 25% heat-
inactivated horse serum, 25% EBSS supple- 
mented with 36 mM D-glucose, 100 U·mL–1 penicillin, 
100 μg·mL–1 streptomycin and 250 ng·mL–1 ampho- 
tericin B). Cultures were incubated in 5% CO2/95% 
humidified air at 37 °C for a total of six days in vitro 
(DIV). 
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Figure 1 Experimental setup for the time-lapse recording of 
NP within lesions of spinal cord slice cultures. (a) Schematic 
diagram depicting the experimental manipulations 
performed in the study. 
(1) Mouse spinal cords were sliced in the longitudinal 
parasagittal plane and cultured within inserts for a total of 6 
DIV. Slices were lesioned at 1 DIV using a double-bladed 
scalpel. (2) NPs were added into slice lesions at 6 DIV 
using a P2 Gilson pipette and a dissection microscope at 
×12.5 magnification. (3) Slices were maintained in an 
incubation chamber, and imaged for 6–24 h using an upright 
time-lapse microscope. (b) Photograph demonstrating the 
procedure of lesioning slices (open arrow) with a 
double- bladed scalpel (arrow), within slice culture 
inserts. A “tab” of culture membrane (arrowhead) was 
clamped against the insert wall using forceps to keep 
the slice stationary. (c) Photograph showing the addition 
of NPs in a pipette tip (arrow) to the lesions of slices (open 
arrow) within culture inserts. (d) The time-lapse recording 
setup consisting of: (1) computer monitor showing a 
recording in progress; (2) controllers for (from top 
downwards) the brightfield lightsource, incubator 
thermoregulator, and microscope stage/column; (3) upright 
time-lapse microscope with motorised stage/column and 
incubator with regulated temperature and gas supply; (4) 
UV lightsource; and (5) computer. (e) The incubation 
chamber in situ, containing slices. 
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The lesioning procedure (Figs. 1(a)(1) and 1(b)) 
was conducted within a laminar flow hood using a 
dissec- tion microscope at ×12.5 magnification. 
Slices were focally lesioned using a double-bladed 
scalpel (size 15 surgical blades) with small lateral 
movements made to ensure the complete 
severance of nerve fibre tracts. The slice debris 
between the two lesion margins was subsequently 
removed using an aspirator, fitted with a 200 μL 
pipette tip, leaving well-defined lesion margins 
(verified by microscopic analysis) approximately 
440 μm apart. This allows for easy visualisation 
of cellular NP uptake dynamics within the injury 
site. Spinal cord slices were lesioned at 1 DIV then 
main- tained until 6 DIV for all experiments, as a 
peak in microglial infiltration has previously been 
shown by ourselves to occur at five days post-
lesioning [20]. 
 
2.3 Delivery of NPs into lesioned slices 
A dissection  microscope  at  ×12.5  magnification 
and a manual pipette were used to deliver 
Sphero NPs (suspended in fresh  slice  culture  
medium  at 20 μg·mL–1; 0.75 μL dose) into the 
lesion of each slice (Figs. 1(a)(2) and 1(c)). The 
feasibility of using an automated NP delivery device 
(i.e. Nanoject IITM Auto- Nanoliter Injector) was 
assessed (data  not  shown), but due to the 
prolonged setup time and additional experimental 
manipulations required, a manual pipette was 
considered sufficient for this study. Slices were 
incubated with NPs for 6 h, as substantial cellular 
uptake occurs within this time period [14, 24, 25]. All 
slices were fixed in 4% paraformaldehyde (PFA; 20 
min; room temperature (RT)). The NP 
concentration and volume applied was optimised in 
pilot experiments, as volumes greater than 1 μL 
resulted in lateral spread of NPs around the lesioned 
slice, and NP concentrations lower than 20 μg·mL–1 
limited  the  NPs  available for cellular uptake 
within the lesion site, hindering quantification of 
uptake (data not shown). 
 
2.4 Time-lapse imaging experiments 
 
Lesioned spinal cord slices (within 35 mm Petri 
dishes) at six DIV were placed in an incubation 
chamber (preheated to 37 °C; 5% CO2/95% 
humidified air; Figs. 1(a)(3), 1(d) and 1(e)) on an 
upright time-lapse microscope (Axiozoom V16, 
AxioCam ICm1 camera; 
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Carl Zeiss, Germany). Time-lapse imaging commenced 
within 10 min of NP addition. Lesioned slices without 
NPs were similarly recorded at 6 DIV to observe the 
cellular activity within injury sites. For all experiments, 
transmitted  light  images  (auto  exposure;  average 
6 ms) were captured every 2 min, with counterpart 
fluorescence imaging (fixed at 50 ms) for NP addition 
experiments. Z-stack imaging was used at each 
time- point to allow compensation for the limited focal 
drift observed in pilot experiments. Video files from 
each imaging session were created using ZEN 
software (Blue Ed., v.1.1.1.0, Carl Zeiss, Germany) 
and Premiere Elements 7 (Adobe, USA). 
 
2.5 Assessment of lesioned slice viability post-
live cell imaging 
 
To assess whether the imaging procedures had 
adverse effects on slice viability, control lesioned slices 
without NPs were stained following time-lapse imaging 
experi- ments (n = 4) and DEX treatment (n = 3). 
The high viability (ca. 96%) of control unlesioned 
slices was previously demonstrated. Slices were 
washed three times in phosphate buffered saline 
(PBS) and incubated for 15 min at 37 °C with calcein 
(1 μL·mL–1) and ethi- dium homodimer (3 μL·mL–1) 
to label live and dead cells respectively. Slices were 
washed three times in PBS and mounted in 
Vectashield mounting medium with DAPI. 
Consistent camera exposure settings were used for 
both fluorescent channels, with images converted to 
grayscale. Corrected integrated density 
measurements were performed using ImageJ software 
(version 1.45s; NIH) and the values for the live stained 
micrograph expressed as a percentage of the sum 
total from both [20, 26]. 
 
2.6 DEX treatment of slices to induce 
microglial suppression 
 
For microglial suppression experiments, an 80% 
medium change was performed at 1 DIV and every 
two days thereafter with culture medium containing 
DEX (10 μM final concentration). This concentration 
is within the range that has previously been shown 
to maximally affect various cell types in vitro [27, 28]. 
Additionally, 5 μL of DEX culture medium was applied 
daily directly into slice lesions to ensure sustained 
 
delivery of drug within the lesion site. This small 
volume was used to limit the quantity of medium 
covering the slices, a critical factor in the maintenance 
of slice viability at the air-medium interface [22, 23]. 
The overall viability of live/dead stained control slices 
treated with DEX was quantified to assess the safety 
of the method of treatment. 
 
2.7 Comparative NP incubations with isolated 
high purity astrocyte populations 
 
NP uptake experiments have previously been per- 
formed in our lab using high purity astrocyte cultures 
(ca. 98% GFAP+) derived from cerebral cortices 
of neonatal Sprague-Dawley rats using an 
established procedure [29]. Briefly, enzymatically-
detached astro- cytes were plated on poly-D-lysine 
(PDL)-coated cover- slips (4 × 104 cells·cm–2) in D10 
medium (Dulbecco’s modified Eagle’s medium, 1 
mM sodium pyruvate, 50 mg·mL–1 streptomycin, 50 
U·mL–1 penicillin, 10% fetal bovine serum and 2 mM 
glutaMAX-I) at 37 °C in humidified 5% CO2/95% air. 
After 24 h, Sphero NPs were added at 20 ng·mL–1 
and incubated for 4 h, then fixed and 
immunocytochemically stained as detailed below. 
The date from these experiments was used to 
demonstrate the differences in NP uptake when 
using isolated purified cells, versus those in the injury 
simulated environment containing microglia. 
 
2.8 Immunocytochemistry 
 
Slices were washed three times in PBS before 
and after fixation with 4% PFA (20 min; RT). Samples 
were incubated in blocker consisting of 5% normal 
donkey serum (10% for lectin staining) in PBS (with 
0.3% Triton X-100 for TUJ-1, MBP and GFAP 
staining), with lectin (1:200 in blocker) or primary 
antibodies (TUJ-1 1:1,000; MBP 1:200; GFAP 1:500; 
CD11b 1:125; Cx3cr1 
1:100; 24 h at 4 °C). Following three PBS washes, 
samples were incubated with appropriate FITC- 
conjugated secondary antibodies (4 h at RT or 4 
°C). Slices were subsequently washed three times  
with PBS and mounted with Vectashield mounting 
medium containing DAPI. 
 
2.9 Fluorescence imaging: Fixed slices 
 
Slices were visualised at ×200 magnification on an 
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Axio Scope A1 fluorescence microscope (Carl 
Zeiss MicroImaging GmbH; Germany)  fitted  with  
an Axio Cam ICc1 digital camera and AxioVision 
software. Where applicable, fluorescence images 
of immunostained slices were merged/stitched using 
Photoshop CS5.1 (version 12.1) allowing 
assessment of entire lesions. 
 
2.10 Quantification of microglial infiltration (± DEX 
treatment) 
 
The total number of lectin-reactive (lectin+) microglia 
within each lesion was divided by the total area of 
the lesion (mm2) to account for differences in slice 
width (dorsal-ventral). Average values for microglial 
density were calculated for lesions within DEX-treated 
and control slices (n ≥ 4 per group). 
 
2.11 Assessment of extent of NP uptake 
within lesioned slices within microglia and 
astrocytes 
 
NP-labelled astrocytes and microglia (GFAP+ and 
lectin-reactive respectively; the neural cell types with 
the most extensive particle uptake profiles in isolated 
cell cultures) were counted within lesion areas and 
expressed as a percentage of the total number of 
cells (n ≥ 3 per group). The extent of NP 
accumulation in individual cells was assessed semi-
quantitatively by comparing the area of NP 
accumulation with the aver- age cross-sectional area 
of an astrocyte or microglial nucleus, as appropriate 
using a previously validated method for nanoparticle 
uptake quantification [14]. The extent of NP uptake 
by each cell was scored as: “low” (less than 10% of 
the average area of a nucleus); “medium” (10%–50%); 
or “high” (>50%). Only NPs that were clearly 
intracellular were included in analyses. 
 
2.12 Statistical analysis 
 
The number of experiments, n, refers to slices obtained 
across different animals and litters. Prism v5.0 software 
(GraphPad, USA) was used for statistical 
analyses. Data are expressed as mean ± standard 
error of the mean (SEM). Live/dead viability 
analysis: Student’s t-test (two-tailed) with Welch’s 
correction was used to compare viability of lesioned 
slices following recording or DEX treatment. 
Microglial infiltration analysis: Student’s  t-test  (two-
tailed)  was  used  to  compare 
 
microglial infiltration ± DEX treatment. NP uptake 
analysis: Data were square root transformed and a one- 
way analysis of variance (ANOVA) conducted using 
Bonferroni’s multiple comparison test for post-hoc 
analysis (a Bartlett’s test was performed to examine 
homogeneity of variance) to detect differences in 
astrocyte and microglial NP uptake ± DEX treatment. 
Extent of NP uptake analysis: Student’s t-test (two- 
tailed) with Welch’s correction was used to detect 
differences in the extent of astrocyte and microglial 
NP uptake ± DEX treatment. 
 
3 Results 
3.1 Validation of NP delivery and time-lapse 
recording methodology 
 
The use of a pipette for NP delivery into spinal cord 
slices proved to be a simple and effective method 
to achieve focal particle delivery into lesion  sites 
(Fig. 2(a)). A dissection microscope facilitated accurate 
guidance of the pipette tip to the lesion site, and live 
assessment of the distribution of NP solution with 
respect to the lesion site. Fluorescence 
micrographs of live/dead stained slices captured 
immediately following time-lapse experiments (Fig. 
2(b)) revealed a high proportion of viable cells in 
the body of the slice with the few dead cells typically 
located around the slice edges and in the vicinity of 
the lesion site, suggesting the procedure is without 
acute adverse effects. Indeed, lesioned slice viability 
following time- lapse recording experiments was 
95.8% ± 2.0% (live/ dead assay; n = 4), which is in 
accordance with our previous values for slices 
maintained in conventional incubators [20]. 
 
3.2 Time-lapse recordings of NP uptake by 
cells within slice lesions and identification of cell 
phenotype 
 
Recordings of control slices 5 days post-lesion induc- 
tion revealed a population of highly motile cells with a 
rounded morphology within the margins of lesions 
(Video S1 in the Electronic Supplementary Material 
(ESM)) suggestive of a microglial phenotype; these 
cells also appeared to be highly proliferative (Fig. 3(a) 
and Video S2 in the ESM) with frequent cell divisions 
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Figure 2   Validation of NP delivery and slice viability for time-lapse recording experiments. Representative fluorescence 
micrographs of lesioned slices, generated at P1, lesioned at 1 DIV and fixed at 6 DIV (white broken lines demarcate 
margins). (a) Nuclear staining (DAPI) reveals lesion margins, and demonstrates focal delivery of NPs into the lesion site. 
(b) Live/dead-staining shows high viability in a lesioned slice following 6 h time-lapse recording. 
 
 
Figure 3 Introduction of NPs into spinal cord lesions results in rapid and extensive NP accumulation by microglia. (a) Merged 
transmitted light and fluorescence micrographs of dividing microglia within the lesion margins of a P1-derived slice (lesioned 
at 1 DIV, fluorescent NPs added 5 days later and incubated for 6 h), with individual frame numbers corresponding to 
Video S2 in the ESM. (b)–(d) Merged transmitted light and fluorescence micrographs (different slice to (a); 10, 190 and 550 
min post-particle addition), with individual frame numbers corresponding to Video S3 in the ESM. Cells displaying 
morphologies and activity typical of microglia predominate within the lesion and demonstrate a time-dependent increase in 
particle accumulation (black arrows and dotted circle). (e) A fluorescent micrograph of the same field as (b)–(d) (arrows 
indicate same cells), fixed at 600 min post-particle addition, shows that the marked cells are lectin-reactive microglia. 
Note the rounded morphology of lectin-reactive cells displaying large NP accumulations. 
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observed. Following the addition of NPs into lesion 
sites, rounded highly active cells could be observed 
to respond to particle addition with highly motile 
activity and engulfment with evidence of rapid 
membrane reorganisation (extrusion and withdrawal). 
This resulted in high accumulation of NPs by this cell 
population, and the extent of intracellular particle 
accumulations could clearly be seen to increase 
over the duration of the recordings (Figs. 3(b)–3(d) 
and Video S3 in the ESM). Post-imaging, it proved 
simple to identify cells whose behaviours were 
recorded in imaging studies through 
immunocytochemical staining for cell type-specific 
markers. This was achieved by marking (prior to 
fixation) the lesion edge from which recordings were 
made and noting distinctive anato- mical features at 
the margin, including curvature of lesions, distinctive 
NP clusters and so on. Staining of 
slices post-recording clearly revealed this rounded 
motile population with prominent engulfing beha- 
viours to be lectin-reactive microglia (Fig. 3(e) and 
Video S3 in the ESM). 
 
3.3 Immunocytochemical staining of lesioned 
slices to identify cell populations showing NP 
internalisation 
Detailed analyses were conducted in order to identify 
specific cell sub-types associated with NP uptake within 
lesions. In keeping with findings from time-lapse 
recordings (Fig. 3(e)), lectin-reactive microglia in slice 
lesions displayed large accumulations of NPs  and 
had rounded morphologies, indicative of microglial 
activation (Fig. 4(a)). In contrast the microglia found 
within the body of slices displayed multiple ramified 
processes characteristic of “resting” (non-activated) 
cells  (Fig. 4(b)). Microglial  identity  was  confirmed 
 
 
Figure 4 Microglia outcompete other neural cells for NPs in the multicellular environment of slice lesion sites. (a) Microglia in 
lesion sites take up NPs avidly and display characteristically large accumulations. Note the rounded morphologies associated 
with phenotypically “activated” microglia. (b) By contrast, microglia within the body of the slice exhibited ramified 
morphologies (arrows), typical of an “unactivated” state. For comparison, insets show rounded, amoeboid cells within a 
lesion (line marks lesion edge), immunostained with 
microglial markers Cx3cr1 and CD11b (arrows indicate same cells in each image). (c) Astrocytes in high purity isolated cultures 
(propagated on tissue culture plastic) exhibit large accumulations of Sphero NPs (20 µg·mL–1, 4 h) [18, 22]. (d) GFAP+ cells 
show little evidence of NP uptake with NP localisation in rounded GFAP
– 
cells. (e) No evidence of NP uptake was observed 
in MBP+ oligodendrocytes. (f) Very limited evidence of NP uptake was observed in the cell bodies of TUJ-1+ neurons (e.g. 
arrowhead). For (d)–(f), note that the surrounding GFAP
–
/MBP
–
/TUJ-1
– 
cells exhibit large NP accumulation, characteristic of 
microglia (arrows). 
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using three specific markers: lectin, Cx3cr1 and CD11b 
(Fig. 4(b)). Astrocytes in high purity 2-D cultures 
have previously been shown by us to extensively 
internalise Sphero NPs, following comparable incuba- 
tion periods [14, 25] (same NP concentration; also 
see Fig. 4(c) for internalisation by astrocytes in 
isolated, high purity primary-derived cultures). By 
contrast, astrocytes in slice cultures exhibited far 
lower NP uptake levels (in terms of both 
proportions of cells labelled and the extent of NP 
accumulation). Indeed, overall there was little 
evidence of NP uptake by the GFAP+ astrocytes 
within the multicellular environment of the slice 
lesions, including at the lesion margins (Fig. 4(d)). 
Similarly, MBP+ oligodendrocytes (Fig. 4(e)) and TUJ-
1+ neurons (Fig. 4(f)), showed negligible particle 
uptake; in every instance, NP accumulations 
were overwhelmingly associated with cells that were 
negative for markers of these major neural cell types, 
highlighting that delivered NPs were almost exclu- 
sively localised to the microglial population. 
 
3.4 Dexamethasone treatment reduces the 
infiltration and NP uptake profiles of microglia 
DEX treatment of lesioned slices did not affect overall 
viability (live/dead assay; >97% fluorescence intensity 
being attributable to calcein (live cells) in all slices; 
two-tailed Student’s t test versus lesioned slices 
without DEX ; n = 3), with the number of dead cells 
within and around the lesion site being similar to 
controls (Fig. 5(a)). Immunocytochemical staining of 
DEX treated lesioned  slices  showed  low  numbers 
of lectin-reactive microglia in lesion sites (Fig. 5(b)). 
 
 
Figure 5 Semi-quantitative evaluation of the effect of DEX treatment on microglial uptake of NPs compared to astrocytes. (a) 
Representative fluorescence micrograph of a live/dead-stained lesioned slice following 5 days of DEX treatment. (b) 
Representative fluorescence micrograph showing reductions in both the number of lectin-reactive microglia and extent of 
NP accumulation in lesions. Occasionally, microglia with large accumulations were apparent (arrows). (c) Representative 
fluorescence micrograph of DEX-treated slice showing GFAP+ astrocytes with a low level of NP labelling (arrows). GFAP– 
cells (arrowheads, pointing leftwards) typically exhibited lower levels of NP uptake than GFAP– cells in untreated controls. 
(d) Bar graph showing a significant reduction in the number of lectin-reactive microglia within the lesions following 5 days 
of DEX treatment (***p < 0.001; n ≥ 4). (e) Bar graph showing that, in lesions, a significantly greater proportion of microglia 
than astrocytes exhibited NP uptake (***p < 0.001; n ≥ 3 per group). A smaller percentage of microglia were NP-labelled in 
DEX-treated slices (**p < 0.01). (f) Bar graph comparing the extent of NP uptake by microglia and astrocytes in DEX-
treated slices and controls. The majority of labelled astrocytes exhibited low levels of NP accumulation (regardless of DEX 
treatment) with no astrocytes showing high levels of accumulation. Microglia exhibited low, medium and high levels of NP 
accumulation, with the proportion of medium labelling being significantly reduced by DEX treatment (***p < 0.001; n ≥ 3 per 
group). 
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Occasionally,  microglial  cells  were  observed  with 
high levels of NP accumulation, comparable to slices 
without  DEX  (arrows  in  Fig. 5(b)),  but  fewer  cells 
exhibited NP uptake overall (compare Fig. 5(b) with 
Fig. 4(a)). Compared to control slices without DEX, 
there was greater evidence of NP uptake by GFAP+ 
astrocytes in lesions (compare Fig. 5(c) with Fig. 4(d)). 
Quantification of the extent of microglial infiltration into 
lesions showed reduced numbers of microglia 
following  DEX  treatment  compared  to  untreated 
controls  (Fig. 5(d)).  A quantitative  analysis  of  the 
proportions  of  microglia  and  astrocytes  displaying 
NP labelling within lesion sites in the absence of DEX 
treatment (Fig. 5(e)) showed that a significantly greater 
percentage of microglia was labelled than astrocytes 
(ca. 5-fold more). In DEX treated slices, the proportion 
of microglia exhibiting NP uptake was significantly 
reduced. This percentage was still greater than the 
proportion of astrocytes labelled on average. Further, 
while  visual  observations  revealed  that  astrocytes 
showed larger accumulations in DEX treated cultures, 
this was not found to be statistically significant. A 
semi-quantitative  analysis  of  the  extent  of  particle 
accumulation  in  NP-labelled  cells  (Fig. 5(f))  shows 
predominantly “low” levels in astrocytes, with <5% of 
cells showing “medium” and no astrocytes exhibiting 
“high” levels of accumulation: This pattern of labelling 
did not change with DEX treatment. In comparison to 
astrocytes, microglia displayed cells with “high” and 
“medium” levels of labelling, with the percentage of 
cells exhibiting “medium” levels being significantly 
reduced with DEX treatment. 
 
4 Discussion 
Sequestration of particles delivered to the CNS 
parenchyma by the resident neural immune cells (the 
microglia), represents a major translational challenge 
confronting the delivery of NP-based therapeutics to 
areas of neurological injury and disease. As microglial 
sequestration is a critical determinant of the eventual 
fate of administered particles, experimental research 
critically requires model systems that simulate mi- 
croglial responses to delivered therapeutic particles 
within a pathological environment. Here, we demon- 
strate the utility of our novel SCI model to examine the 
interactions of major neural cell types (that play key 
roles in injury and repair) with NPs within a site of 
neurological injury. Notably, we were able to demon- 
strate for the first time in real-time, the surveillance 
behaviours of intra-lesional microglia and their 
avid response to the delivered NPs. Such microglial 
clearance of nanotherapeutic agents is an important 
area for CNS drug discovery and nanotechnology 
research, but the rate of progress in this field is 
hampered by the absence of available experimental 
models in which the immune cell component of path- 
ology sites can be adequately and easily mimicked. 
We consider that our model can serve as a 
valuable tool offering the technical ease of in vitro 
handling, with the pathological complexity of injury 
sites. Consequently, we consider that demonstration  
of the handling of nanoparticles by slice microglia, 
with proof of similarities to the in vivo situation (as 
shown in this study) is an important outcome, and 
can be predicted to be of high use in translational 
and pharmaceutical studies. This  could  be  via  the  
use of immune suppressive treatment (that can 
alter microglial numbers/function, as shown here), 
the use of the so called “stealth coatings” to evade 
immune cell uptake or even stem cell transplantation 
that has been suggested to reduce immune 
activation, highlighting the versatility of our model for 
therapeutic testing. 
Importantly, we prove using the model that admini- 
stration of an anti-inflammatory drug (DEX) that is 
currently used widely in clinical neurology, including 
for the treatment of acute SCI, can reduce the infiltra- 
tion of the injury site by microglia, a phenomenon 
that is entirely consistent with the reported effects of 
DEX in vivo [30]. In turn this reduction in the cellular 
response of microglia was clearly shown to limit their 
sequestration of NPs. This highlights the utility of our 
“reductionist” model for the developmental testing 
of pharmaceutical strategies to limit the sequestration 
of therapeutic NPs by neural immune cells. 
A few different approaches have been taken to 
mimic SCI pathology in vitro including: monoculture 
systems (primary and cell lines), co-culture systems, 
microfluidic devices and organotypic slice cultures 
[31–37]. A number of factors must be taken into con- 
sideration when evaluating the utility of each model 
system  including  the  ability  to  mimic  intercellular 
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uptake dynamics, definition of cellular ratios to model 
specific CNS regions/disease states, 
standardisation of protein coronas around introduced 
nanoparticles, ease of nanoparticle delivery, and 
amenability to various (including real-time) imaging 
techniques [9]. Microfluidics models usually  (and  
mono-cultures by definition) do not contain all the 
major cell types present in the CNS and thus fail to 
mimic the complex multi-faceted components of SCI 
pathology, which limits their value in the context of NP 
uptake experiments. Co-culture systems often do not 
contain microglial cells, a significant omission given 
their dominant uptake profiles, and usually also lack 
simulated injury [9, 14]. A few laboratories have 
simulated SCI in organotypic spinal cord slice 
cultures, which contain multiple cell types within in 
vivo-relevant cytoarchitecture. However, two of these 
models were established by weight drop onto slices, 
which is not suitable for assessing NP uptake in 
clearly-demarcated lesion sites, and while these 
models mimicked some of the responses to injury in 
vivo overall the characterisation of pathology was 
basic (e.g. cell death) [33, 36]. Another SCI model 
has been established based on induction of complete 
transecting injury in parasagittal organotypic spinal 
cord slices from neonatal mice [23]. However, cardinal 
neuropathological responses were only characterised 
in the neurons, neglecting neuroglial responses. An 
elegant model has been established that contains 
neurons and the major neuroglial cells, by seeding 
dissociated rat embryonic spinal cord on top of an 
astrocyte monolayer [37]. The mechanical induction 
of injury resulted in a lesion site with many of the 
cardinal pathological responses displayed by multiple 
cell types (demyelination, reactive astrocytosis, neurite 
degeneration and, importantly, microglial infiltration). 
This model is better defined and the induced injury 
produces a lesion site better-suited to NP uptake 
studies than the other models reported. However, we 
suggest that the cytoarchitecture of the spinal cord 
and potentially, therefore, some of the complex cell- 
ECM signalling present in vivo, is better mimicked in 
organotypic slice cultures. Indeed, in the context of 
model development for laboratory research, it has 
recently been suggested that the best experimental 
predictability is offered by organotypic slice models 
that can replicate the microenvironment of the donor 
 
tissue [38]. Our model is consistent with this paradigm. 
We consider therefore that the system developed by 
ourselves can provide clinically relevant insights into 
the fate of NPs delivered to neuropathology  sites. 
Our injury-simulating model offers major benefits for 
regenerative neurology as a neuromimetic screening 
system given: (a) The full complement of neural cell 
subclasses is present in the slice arrays and can 
be easily detected using standard procedures; (b) the 
use of humane procedures to derive tissue and 
reduce reliance on live animal experiments; (c) the 
simplicity/ cost effectiveness of the methods and 
reagents used; 
(d) several slices (up to seven) can be derived from 
a single animal at the donor ages used, 
significantly reducing animal usage; (e) reduced 
biological variabi- lity as both experimental and 
control slices can be derived from the same 
animal; (f) the derivation of organotypic spinal cord 
slices from human  tissue has been proved feasible 
highlighting the clinical utility of the model [39]; (g) 
the ease of experimental manipulation and 
compatibility of the model with a wide range of 
imaging methods, including time lapse and confocal 
microscopy. The compatibility of time- lapse imaging 
whilst retaining slice viability was verified by 
live/dead staining; the capture of cellular NP uptake 
events within slice lesion sites also proved feasible. 
Introduction of NPs into the injured tissue was 
simple and rapid to perform, demonstrating the 
versatility of the injury model, which can therefore be 
used to study cellular interactions with a wide range of 
NPs/materials. Further, post-culture immunostaining 
of slices facilitated the direct identification of time- 
lapse imaged cells and permitted the assessment 
of NP uptake across different cell types. Less 
obviously, a single growth medium is required to 
culture the slices, overcoming issues related to 
differential biomo- lecular corona formation when 
different biological media are used to culture 
individual cell types [9]. This can significantly affect 
NP uptake and is a major confounding factor in 
comparative and cross-cellular studies of NP uptake 
[9, 10]. 
While microglia will present a  critical  challenge 
for delivery strategies to the CNS, this is currently a 
poorly studied area in neuro-nanotechnology. Such 
impediments to the clinical translation of therapeutic 
nanoparticles  raise  important  issues  regarding  the 
13 Nano Res. 
 
 
 
 
necessity to develop interventions to overcome the 
microglial barrier (in order to enhance bioavailability 
to other target neural cell types in the CNS). Clearly, 
the use of immunosuppressive or immunomodulatory 
therapies to reduce microglial activity could constitute 
one such clinically relevant approach. In this regard, 
the corticosteroid DEX is commonly prescribed as 
an immunosuppressive therapy  following  injuries to 
the CNS [40, 41] and acts by inhibiting microglial 
proliferation [42], reducing their migratory capabilities 
[43] and potentially increasing microglial apoptosis 
[44, 45]. In keeping with this role of DEX in vivo, we 
observed a significant reduction in the numbers of 
microglia in slice lesion sites. The extent of NP 
accu- mulation within microglia was also reduced—
which would have predicted increased extracellular 
availabi- lity of NPs to other neural cell types. 
However, in our study we observed only the 
suggestion of an increase in astrocyte labelling with 
no apparent enhancement of particle uptake in other 
neural cell types. The reasons for this lack of effect 
are not clear at present, and DEX-induced 
impairment of endocytic processes in other (non-
microglial) neural cell types cannot be ruled out. 
The use of different immunosuppressive drugs and 
longer treatment regimens would prove interesting 
in this regard. In this context, we recently showed 
that even when a small population of microglia (less 
than 5%) are present within high purity mono- 
cultures of astrocytes, oligodendrocyte precursors and 
oligodendrocytes, NP uptake by the non-microglial 
cells is dramatically limited due to avid microglial 
sequestration [10]. This underscores the highly respon- 
sive nature of the microglial response, for identification 
and removal of foreign materials from the CNS. 
Consequently, even a small residual population of 
microglia within the lesion sites persisting after DEX 
treatment may have been sufficient to dramatically 
limit particle uptake in other cell types. 
Nonetheless, our findings do highlight the utility 
of our model as a screening system for strategies 
that promote evasion of the neural immune 
component, in order to optimise the use of NP-
based approaches for neuropharmacology and 
nanotherapeutics. We consider that the use of 
similar experimental models based on 3-D 
organotypic slices derived from other types of 
biological tissues, has great potential for the 
 
screening of nanotherapeutic agents for a spectrum 
of disease and injury. As such, we consider that our 
approach has high relevance to the nanotechnology 
community in the developmental testing of phar- 
maceutical interventions based on nanotherapeutic 
agents. 
 
5 Conclusions 
We demonstrate the multiple advantages offered by 
a 3-D simulation of SCI (based on organotypic slice 
cultures of spinal cord tissue), to examine the fate 
of NPs delivered into areas of neural pathology, 
specifically their uptake by the resident immune cells. 
Dynamic live-cell imaging and histological assessment 
following NP delivery into slice injury sites revealed 
in real-time the well-documented phenomenon of 
competitive sequestration of particles by infiltrating 
microglia—a process that markedly reduced uptake 
in other neural cells in the injury sites. Use of 
immunosuppressive DEX-treatment proved to be an 
effective means to reduce microglial sequestration of 
particles. These results provide a real-time demon- 
stration of the major intrinsic neural immune barrier 
that exists in the context of CNS-targeted nanothe- 
rapeutics. Our biological  model  therefore  provides 
an alternative platform to test strategies to promote 
evasion of microglial clearance of  biomaterials 
whilst reducing the use of live animal injury models 
for developmental testing of such interventions, in 
nanotechnology research. 
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